CYP2C9*3 polymorphism presenting as lethal subdural hematoma with low-dose warfarin.

about

Genetics of the patent ductus arteriosus (PDA) and pharmacogenetics of PDA treatment.

P2860

Q50420641-804B83A2-6CC7-47E9-A66B-D5D7B8407B61

P2860

CYP2C9*3 polymorphism presenting as lethal subdural hematoma with low-dose warfarin.

Item

http://www.wikidata.org/entity/Q42703942

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

CYP2C9*3 polymorphism presenting as lethal subdural hematoma with low-dose warfarin.

@en

CYP2C9*3 polymorphism presenting as lethal subdural hematoma with low-dose warfarin.

@nl

type

Item

label

CYP2C9*3 polymorphism presenting as lethal subdural hematoma with low-dose warfarin.

@en

CYP2C9*3 polymorphism presenting as lethal subdural hematoma with low-dose warfarin.

@nl

prefLabel

CYP2C9*3 polymorphism presenting as lethal subdural hematoma with low-dose warfarin.

@en

CYP2C9*3 polymorphism presenting as lethal subdural hematoma with low-dose warfarin.

@nl

P1476

CYP2C9*3 polymorphism presenting as lethal subdural hematoma with low-dose warfarin.

@en

P2093

D Tiwari

http://www.w3.org/2001/XMLSchema#string

Kannan Sridharan

http://www.w3.org/2001/XMLSchema#string

Niteen D Karnik

http://www.w3.org/2001/XMLSchema#string

V Gupta

http://www.w3.org/2001/XMLSchema#string

P2860

Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis.

Role of pharmacogenomics in drug discovery and development.

Pharmacogenetic aspects of coumarinic oral anticoagulant therapies.

Should we be applying warfarin pharmacogenetics to clinical practice? No, not now.

Variability in CYP2C9 allele frequency: a pilot study of its predicted impact on warfarin response among healthy South and North Indians.

[Association between CYP2C9 and VKORC1 genetic polymorphism and warfarin dose requirements].

Validation of warfarin pharmacogenetic algorithms in clinical practice.

A randomized trial of genotype-guided dosing of warfarin.

Optimization of warfarin dose by population-specific pharmacogenomic algorithm.

P304

549-550

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.4103/0253-7613.140594

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266682537

http://www.w3.org/2001/XMLSchema#string

P698

25298588

http://www.w3.org/2001/XMLSchema#string

P932

4175895

http://www.w3.org/2001/XMLSchema#string

CYP2C9*3 polymorphism presenting as lethal subdural hematoma with low-dose warfarin.

about

P2860

P2860

CYP2C9*3 polymorphism presenting as lethal subdural hematoma with low-dose warfarin.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P932